Keep up to date on the latest medical news at MDLinx - FREE!


  • Stay current on the latest medical literature, research and clinical news
  • MD jobs and physician job search at our new medical job Career Center
  • Receive invitations to paid market research
  • Search Clinical Trials and Medical Conferences

register to view free medical at articles at MDLinx

Follow Us

Posts by category

MDLinx Blog - Medical News and more.

Current Articles | RSS Feed RSS Feed

FDA: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod)

  
  
  
  
  

FDA issues drug safety annoucement for multiple sclerosis drug Gilenya (fingolimod).

The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod). The agency also has evaluated additional clinical trial and postmarket data for Gilenya, including reports of patients who died of cardiovascular events or unknown causes. FDA could not definitively conclude that Gilenya was related to any of the deaths (see Data Summary, below). However, based on its reevaluation of the data, FDA remains concerned about the cardiovascular effects of Gilenya after the first dose. Data show that, although the maximum heart rate lowering effect of Gilenya usually occurs within 6 hours of the first dose, the maximum effect may occur as late as 20 hours after the first dose in some patients (See Data Summary).

For this reason, Gilenya is now contraindicated (FDA advises against its use) in patients with certain pre-existing or recent (within last 6 months) heart conditions or stroke, or who are taking certain antiarrhythmic medications. See CONTRAINDICATION section of the drug label2.

FDA continues to recommend that all patients starting Gilenya be monitored for signs of a slow heart rate (bradycardia) for at least 6 hours after the first dose. FDA is now recommending hourly pulse and blood pressure measurement for all patients starting Gilenya. Electrocardiogram (ECG or EKG) testing should be performed prior to dosing and at the end of the observation period. Cardiovascular monitoring should continue until any symptoms resolve.

Read full release here.

Trending Medical Articles

Friday, Jul 18, 2014
Obesity Surgery, 07/18/2014 Leonetti F, et al. – Researchers assessed the effectiveness of a sequential diet regimen called the "obese preoperative diet" (OPOD) in morbidly obese patients with and without type 2 diabetes mellitus (T2DM) who were scheduled to undergo laparoscopic bariatric surgery. They concluded that OPOD, including 10 days of a VLCKD, was safe and effective in...Read More
Thursday, Jul 17, 2014
International Urology and Nephrology, 07/17/2014 Chan SYS, et al. – The study aims to investigate the incidence of deep vein thrombosis (DVT) in Chinese patients undergoing robotic–assisted laparoscopic radical prostatectomy (RALP) for prostate cancer and the need for prophylactic anticoagulation. However, study suggest that the post–RALP incidence of DVT in Chinese...Read More